Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866789 | 0.91 | GFER (0.43) | GFERKMT2AMEN1MAPTNPC1 | |
| SCHEMBL4870535 | 0.86 | KMT2A (0.54) | KMT2AMEN1MAPTNPC1HTR7 | |
| SCHEMBL4873316 | 0.82 | MEN1 (0.44) | KMT2AMEN1MAPTHTR7TSHR | |
| SCHEMBL4871230 | 0.82 | GFER (0.56) | GFERHSD17B10KMT2AMEN1MAPT | |
| SCHEMBL4866824 | 0.81 | MEN1 (0.46) | HSD17B10KMT2AMEN1MAPTNPC1 | |
| SCHEMBL4866790 | 0.81 | KMT2A (0.44) | GFERKMT2AMEN1MAPTNPC1 | |
| SCHEMBL4865513 | 0.81 | LMNA (0.45) | GFERKMT2AMEN1MAPTHTR7 | |
| SCHEMBL4870570 | 0.77 | ALDH1A1 (0.44) | GFERKMT2AMEN1MAPTKDM4E | |
| SCHEMBL4866401 | 0.76 | KMT2A (0.50) | KMT2AMEN1MAPTNPC1TSHR | |
| SCHEMBL4866921 | 0.76 | L3MBTL1 (0.43) | GFERKMT2AMEN1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | claimed |
| EP-1366030-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | Neurogen Corporation (US) | 2003-12-03 | — | — | EP | claimed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | claimed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | claimed |
| WO-2002004433-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-17 | — | — | WO | claimed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | GFER 2965/4885HSD17B10 1074/4885KMT2A 1995/4885 |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | GFER 3092/4885HSD17B10 1070/4885KMT2A 2135/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | GFER 2965/4885HSD17B10 1074/4885KMT2A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.